Sugi Predict

Sugi Predict / Targets / HRH4

HRH4

Histamine H4 receptor · Q9H3N8 · HRH4 on Sugi Atlas →

147,789 patent compounds predicted against HRH4, 69,956 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Iodophenpropit Iodophenpropit (SCHEMBL114508) 1.00 20/20
SCHEMBL81467 SCHEMBL81467 0.57 20/20
Clobenpropit Clobenpropit (SCHEMBL49050) 1.00 19/20
SCHEMBL128037 SCHEMBL128037 0.59 15/20
SCHEMBL122996 SCHEMBL122996 0.78 14/20
SCHEMBL84439 SCHEMBL84439 0.54 12/20
Loxapine Loxapine (SCHEMBL94146) 1.00 11/20
SCHEMBL140907 SCHEMBL140907 1.00 11/20
Loxapine Loxapine (SCHEMBL41625) 0.98 11/20
Loxapine Loxapine (SCHEMBL41643) 0.82 11/20
Loxapine Loxapine (SCHEMBL41644) 0.78 11/20
SCHEMBL172210 SCHEMBL172210 0.65 10/20
SCHEMBL161782 SCHEMBL161782 0.63 10/20
SCHEMBL122675 SCHEMBL122675 0.62 10/20
SCHEMBL122676 SCHEMBL122676 0.62 10/20
SCHEMBL123207 SCHEMBL123207 0.62 10/20
SCHEMBL177816 SCHEMBL177816 0.60 10/20
SCHEMBL122950 SCHEMBL122950 0.56 10/20
SCHEMBL123204 SCHEMBL123204 0.56 10/20
SCHEMBL123205 SCHEMBL123205 0.56 10/20

Clinical trials — most relevant to HRH4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant Schizophrenia PHASE4COMPLETED
Regulatory Lymphocytes in Patients Treated With Specific Immunotherapy PHASE4COMPLETED
The Effect of Allergen Immunotherapy on Anti-viral Immunity in Patients With Allergic Asthma PHASE4COMPLETED
Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma PHASE3COMPLETED
Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria. PHASE3NOT_YET_RECRUITING
A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists PHASE3COMPLETED
A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines PHASE3RECRUITING
To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria PHASE3ACTIVE_NOT_RECRUITING
Efficacy and Safety of Chemoattractant Receptor-homologous Molecule Expressed on T Helper Type 2 (CRTh2) Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines PHASE2COMPLETED
A Clinical Trial of HRS-3095 in Patients With Chronic Spontaneous Urticaria PHASE2NOT_YET_RECRUITING
Efficacy and Safety of LEO 152020 Tablets for the Treatment of Adults With Moderate to Severe Atopic Dermatitis PHASE2COMPLETED
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous AGX-201 for Migraine Prophylaxis PHASE2UNKNOWN
A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge PHASE2COMPLETED
Effects of Betahistine Hydrochloride in Overweight Women PHASE1COMPLETED
Evaluation of Histamine H3 Receptor Radioligand [11C]AZ12807110 and Histamine H3 Receptor Occupancy of AZD5213 After Oral Administration PHASE1COMPLETED
A Multiple Ascending Dose, Phase 1b Study of YH35324 in Atopic Healthy Subjects or Subjects With Allergic Diseases PHASE1COMPLETED
Investigation Of a New Oral Anti-Histamine in Healthy Male Subjects PHASE1COMPLETED
Skin Prick Tests With AllerT in Subjects Allergic to Birch Pollen PHASE1COMPLETED
Investigation of the Pruritogens of Liver-related Diseases nanUNKNOWN
Histamine Responsiveness in McCune-Albright Syndrome nanCOMPLETED
The Efficacy of L-cysteine in Prevention of Headache Attacks in Migraine Patients nanCOMPLETED
The Efficacy of L-cysteine in Prevention of Cluster Headache nanCOMPLETED
Applying Systems Immunology to the Search for Personalized Biomarkers of Clinical Efficacy nanCOMPLETED
Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer nanCOMPLETED
Pilot Study: Characterization of the Immune Phenotype of Patients Allergic to Wasp Venom or Penicillin nanCOMPLETED
In Vivo Assessment of Histamine Pharmacodynamics nanWITHDRAWN
The Efficacy in Treatment of Facial Melasma Combined With Thulium 1927-nm Fractional Laser and Topical H2R Antagonist nanCOMPLETED
Dermal Blood Flow Response to Escalating Doses of Histamine, Administered by a Skin Prick nanCOMPLETED
Histamine Pharmacogenetics in Children With Atopic Dermatitis nanCOMPLETED
Unraveling the Pathogenesis of Pruritus in Intrahepatic Cholestasis of Pregnancy nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a HRH4 binder may also engage these)

ProteinNameSimilarity
Q91ZY2 — 0.995 Q91ZY2 →
Q91ZY1 — 0.994 Q91ZY1 →
P31390 — 0.983 P31390 →
P18901 — 0.981 P18901 →
P70174 — 0.981 P70174 →
P79748 — 0.979 P79748 →
DRD1 D(1A) dopamine receptor 0.979 landscape →
O42384 — 0.978 O42384 →
Q02152 — 0.978 Q02152 →
P50130 — 0.978 P50130 →
P42288 — 0.978 P42288 →
Q9N2D9 — 0.978 Q9N2D9 →
P31389 — 0.978 P31389 →
Q95136 — 0.978 Q95136 →
Q9N2B2 — 0.978 Q9N2B2 →
Q9N2B1 — 0.977 Q9N2B1 →
P56490 — 0.977 P56490 →
P30940 — 0.977 P30940 →
DRD2 D(2) dopamine receptor 0.977 landscape →
Q9N2B0 — 0.976 Q9N2B0 →
HTR1B 5-hydroxytryptamine receptor 1B 0.976 landscape →
O77680 — 0.976 O77680 →
P42289 — 0.976 P42289 →
Q61121 — 0.976 Q61121 →
O42385 — 0.976 O42385 →
LPAR1 Lysophosphatidic acid receptor 1 0.976 landscape →
Q91081 — 0.976 Q91081 →
Q9N2A4 — 0.976 Q9N2A4 →
HRH1 Histamine H1 receptor 0.975 landscape →
Q5WA50 — 0.975 Q5WA50 →